High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals
Tóm tắt
To investigate whether monosodium urate (MSU) crystals induce the production of CCL2 (monocyte chemoattractant protein-1; MCP-1) in human fibroblast-like synoviocytes (FLS) and whether this mechanism would be affected by high-density lipoproteins (HDL). Human FLS isolated from synovial tissue explants were stimulated with MSU crystals (0.01 to 0.5 mg/ml) or interleukin (IL)-1β (10 pg/ml) in the presence or absence of HDL (50 and 100 μg/ml). The production and expression of CCL2 was evaluated with ELISA, confocal microscopy, immunofluorescence microscopy, chemotaxis assay, and real-time quantitative PCR. Exposure of FLS to MSU crystals induced CCL2 accumulation in culture medium in a dose- and time-dependent manner, reaching a plateau at 50 to 75 μg/ml MSU crystals and 20 to 24 hours. Although low, the induced CCL2 levels were sufficient to trigger mononuclear cell migration. In resting FLS, CCL2 was localized in small cytoplasmic vesicles whose number diminished with MSU crystal stimulation. Concomitantly, MSU crystals triggered the induction of CCL2 mRNA expression. All these processes were inhibited by HDL, which cause a 50% decrease in CCL2 mRNA levels and a dose-dependent inhibition of the release of CCL2. Similar results were obtained when FLS were pretreated with HDL and washed before activation by MSU crystals or IL-1β, suggesting a direct effect of HDL on the FLS activation state. The present results demonstrate that MSU crystals induce FLS to release CCL2 that is stored in vesicles in resting conditions. This mechanism is inhibited by HDL, which may limit the inflammatory process by diminishing CCL2 production and, in turn, monocytes/macrophages recruitment in joints. This study confirms the antiinflammatory functions of HDL, which might play a part in the limitation of acute gout attack.
Tài liệu tham khảo
Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV, Broxmeyer HE, Charo IF: Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997, 100: 2552-2561. 10.1172/JCI119798.
Rollins BJ: MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5. Cytokine Reference. Edited by: Oppenheim JJ, Feldmann M. 2000, London: Academic Press, 1145-1160.
Berckmans RJ, Nieuwland R, Kraan MC, Schaap MC, Pots D, Smeets TJ, Sturk A, Tak PP: Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther. 2005, 7: R536-R544. 10.1186/ar1706.
Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008, 117: 1649-1657. 10.1161/CIRCULATIONAHA.107.745091.
Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, Hashimoto K, Yamamoto M, Fujio H, Miura A, Ohta K, Morita H, Saito H, Emori T, Nakamura Y, Kusano I, Ohe T: Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J. 2004, 68: 671-676. 10.1253/circj.68.671.
Chensue SW, Warmington KS, Ruth JH, Sanghi PS, Lincoln P, Kunkel SL: Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. J Immunol. 1996, 157: 4602-4608.
Matsukawa A, Miyazaki S, Maeda T, Tanase S, Feng L, Ohkawara S, Yoshinaga M, Yoshimura T: Production and regulation of monocyte chemoattractant protein-1 in lipopolysaccharide- or monosodium urate crystal-induced arthritis in rabbits: roles of tumor necrosis factor alpha, interleukin-1, and interleukin-8. Lab Invest. 1998, 78: 973-985.
Villiger PM, Terkeltaub R, Lotz M: Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. J Clin Invest. 1992, 90: 488-496. 10.1172/JCI115885.
Villiger PM, Terkeltaub R, Lotz M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol. 1992, 149: 722-727.
So A: Developments in the scientific and clinical understanding of gout. Arthritis Res Ther. 2008, 10: 221-
Martin WJ, Walton M, Harper J: Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 2009, 60: 281-289. 10.1002/art.24185.
Ortiz-Bravo E, Sieck MS, Schumacher HR: Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993, 36: 1274-1285. 10.1002/art.1780360912.
Ryckman C, McColl SR, Vandal K, de Médicis R, Lussier A, Poubelle PE, Tessier PA: Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum. 2003, 48: 2310-2320. 10.1002/art.11079.
Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S: Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993, 69: 83-91. 10.1006/clin.1993.1153.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006, 440: 237-241. 10.1038/nature04516.
So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007, 9: R28-10.1186/ar2143.
Ng G, Sharma K, Ward SM, Desrosiers MD, Stephens LA, Schoel WM, Li T, Lowell CA, Ling CC, Amrein MW, Shi Y: Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity. 2008, 29: 807-818. 10.1016/j.immuni.2008.09.013.
Terkeltaub RA: What stops a gouty attack?. J Rheumatol. 1992, 19: 8-10.
Terkeltaub R, Martin J, Curtiss LK, Ginsberg MH: Apolipoprotein B mediates the capacity of low density lipoprotein to suppress neutrophil stimulation by particulates. J Biol Chem. 1986, 261: 15662-15667.
Terkeltaub RA, Dyer CA, Martin J, Curtiss LK: Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest. 1991, 87: 20-26. 10.1172/JCI114971.
Burt HM, Jackson JK, Rowell J: Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals. J Rheumatol. 1989, 16: 809-817.
Kumagai Y, Watanabe W, Kobayashi A, Sato K, Onuma S, Sakamoto H: Inhibitory effect of low density lipoprotein on the inflammation-inducing activity of calcium pyrophosphate dihydrate crystals. J Rheumatol. 2001, 28: 2674-2680.
Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, Burger D: Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001, 97: 2381-2389. 10.1182/blood.V97.8.2381.
Scanu A, Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D: Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J Leukoc Biol. 2008, 83: 921-927. 10.1189/jlb.0807551.
Kanellis J, Watanabe S, Li H, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003, 41: 1287-1293. 10.1161/01.HYP.0000072820.07472.3B.
Umekawa T, Chegini N, Khan SR: Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 2003, 18: 664-669. 10.1093/ndt/gfg140.
Scanu A, Oliviero F, Braghetto L, Ramonda R, Luisetto R, Calabrese F, Pozzuoli A, Punzi L: Synoviocyte cultures from synovial fluid. Reumatismo. 2007, 59: 66-70.
Denko CW, Whitehouse MW: Experimental inflammation induced by natural occurring microcrystalline calcium salts. J Rheumatol. 1976, 3: 54-62.
Burger D, Chicheportiche R, Giri JG, Dayer JM: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995, 96: 38-41. 10.1172/JCI118045.
Oynebraten I, Barois N, Hagelsteen K, Johansen FE, Bakke O, Haraldsen G: Characterization of a novel chemokine-containing storage granule in endothelial cells: evidence for preferential exocytosis mediated by protein kinase A and diacylglycerol. J Immunol. 2005, 175: 5358-5369.
Oynebraten I, Bakke O, Brandtzaeg P, Johansen FE, Haraldsen G: Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood. 2004, 104: 314-320. 10.1182/blood-2003-08-2891.
Zupancic G, Ogden D, Magnus CJ, Wheeler-Jones C, Carter TD: Differential exocytosis from human endothelial cells evoked by high intracellular Ca(2+) concentration. J Physiol. 2002, 544: 741-755. 10.1113/jphysiol.2002.027490.
Schiltz C, Lioté F, Prudhommeaux F, Meunier A, Champy R, Callebert J, Bardin T: Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 2002, 46: 1643-1650. 10.1002/art.10326.
Navab M, Reddy S, Van Lenten BJ, Anantharamaiah GM, Fogelman AM: Role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009, 50 (Suppl): S145-S149. 10.1194/jlr.R800036-JLR200.
Shao B, Heinecke JW: HDL, lipid peroxidation, and atherosclerosis. J Lipid Res. 2009, 50: 599-601. 10.1194/jlr.E900001-JLR200.
Burger D, Dayer JM, Molnarfi N: Cell contact dependence of inflammatory events. Contemporary Targeted Therapies in Rheumatology. Edited by: Smolen JS, Lipsky PE. 2007, Abingdon, UK: Taylor & Francis Books Ltd, 85-103.
Cettour-Rose P, Nguyen TX, Serrander L, Kaufmann MT, Dayer JM, Burger D, Roux-Lombard P: T cell contact-mediated activation of respiratory burst in human polymorphonuclear leukocytes is inhibited by high-density lipoproteins and involves CD18. J Leukoc Biol. 2005, 77: 52-58.
Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, Bernardi D, Ramonda R, Plebani M, Punzi L: Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol. 2009, 27: 79-83.
Wu A, Hinds CJ, Thiemermann C: High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock. 2004, 21: 210-221. 10.1097/01.shk.0000111661.09279.82.
Liu-Bryan R, Lioté F: Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signaling. Joint Bone Spine. 2005, 72: 295-302. 10.1016/j.jbspin.2004.12.010.